











Dose Response Curves

Report Date:December 09, 2013

Test Date:April 08, 2013

All Cell Lines





National Cancer Institute Developmental Therapeutics Program In-Vitro Testing Results

NSC : 771790 / 1	Experiment ID : 1304NS55	Test Type : 08	Units : Molar
Report Date : December 09, 2013	Test Date : April 08, 2013	QNS :	MC :
COMI : NMR/22257580 (124126)	Stain Reagent : SRB Dual-Pass Related	SSPL : 0YAR	

Panel/Cell Line	Log10 Concentration												GI50	TGI	LC50	
	Time Zero	Mean Optical Densities							Percent Growth							
		Ctrl	-8.0	-7.0	-6.0	-5.0	-4.0	-8.0	-7.0	-6.0	-5.0	-4.0				
Leukemia																
CCRF-CEM	0.520	2.797	1.566	0.588	0.551	0.546	0.470	46	3	1	1	-10	< 1.00E-8	1.28E-5	> 1.00E-4	
HL-60(TB)	1.055	2.924	1.293	0.688	0.633	0.497	0.591	13	-35	-40	-53	-44	< 1.00E-8	1.85E-8	.	
K-562	0.205	1.761	0.331	0.283	0.283	0.217	0.186	8	5	5	1	-10	< 1.00E-8	1.18E-5	> 1.00E-4	
MOLT-4	0.758	2.674	2.289	0.952	0.797	0.593	0.451	80	10	2	-22	-41	2.68E-8	1.21E-6	> 1.00E-4	
RPML-8226	0.779	2.599														
SR	0.524	2.575	1.002	0.781	0.694	0.663	0.433	23	13	8	7	-17	< 1.00E-8	1.91E-5	> 1.00E-4	
Non-Small Cell Lung Cancer																
A549/ATCC	0.519	1.979	0.961	0.668	0.616	0.611	0.349	30	10	7	6	-33	< 1.00E-8	1.45E-5	> 1.00E-4	
HOP-62	0.689	2.092	1.177	1.088	1.149	0.990	0.721	35	28	33	21	2	< 1.00E-8	> 1.00E-4	> 1.00E-4	
NCI-H226	1.253	2.463	1.924	1.731	1.477	1.502	1.065	55	39	19	21	-15	< 2.20E-8	3.78E-5	> 1.00E-4	
NCI-H322M	0.599	1.469	0.828	0.770	0.774	0.681	0.461	26	20	20	9	-23	< 1.00E-8	1.95E-5	> 1.00E-4	
NCI-H460	0.340	2.940	0.538	0.377	0.295	0.265	0.116	8	1	-13	-22	-66	< 1.00E-8	1.25E-7	4.33E-5	
NCI-H522	1.247	2.592	1.184	1.103	0.928	0.925	0.579	-5	-12	-26	-26	-54	< 1.00E-8	< 1.00E-8	7.42E-5	
Colon Cancer																
COLO 205	0.470	1.931	0.636	0.460	0.186	0.120	0.289	11	-2	-61	-75	-39	< 1.00E-8	6.84E-8	.	
HCC-2998	0.528	1.723	1.129	0.670	0.694	0.580	0.249	50	12	14	4	-53	1.02E-8	1.19E-5	8.92E-5	
HCT-116	0.264	2.395	0.796	0.587	0.340	0.358	0.200	25	15	4	4	-24	< 1.00E-8	1.42E-5	> 1.00E-4	
HCT-15	0.331	2.350	0.901	0.660	0.546	0.501	0.339	28	16	11	8	.	< 1.00E-8	> 1.00E-4	> 1.00E-4	
HT29	0.260	1.378	0.306	0.255	0.248	0.203	0.143	4	-2	-5	-22	-45	< 1.00E-8	4.80E-8	> 1.00E-4	
KM12	0.665	3.057	1.162	1.080	0.863	0.688	0.250	21	17	8	1	-62	< 1.00E-8	1.03E-5	6.36E-5	
SW-620	0.408	2.573	0.690	0.736	0.685	0.636	0.270	13	15	13	11	-34	< 1.00E-8	1.72E-5	> 1.00E-4	
CNS Cancer																
SF-268	0.612	2.054	1.156	1.068	0.852	0.675	0.473	38	32	17	4	-23	< 1.00E-8	1.45E-5	> 1.00E-4	
SF-295	0.899	2.681	0.768	0.626	0.602	0.619	0.388	-15	-30	-33	-31	-57	< 1.00E-8	< 1.00E-8	5.42E-5	
SF-539	0.979	2.866	1.105	0.737	0.795	0.783	0.624	7	-25	-19	-20	-36	< 1.00E-8	1.63E-8	> 1.00E-4	
SNB-19	0.755	2.191	1.464	1.385	1.289	1.210	0.895	49	44	37	32	10	< 1.00E-8	> 1.00E-4	> 1.00E-4	
SNB-75	0.959	1.829	0.971	1.084	1.176	1.067	0.683	1	14	25	12	-29	< 1.00E-8	2.00E-5	> 1.00E-4	
U251	0.585	2.015	1.095	0.728	0.593	0.575	0.339	36	10	1	-2	-42	< 1.00E-8	1.76E-6	> 1.00E-4	
Melanoma																
LOX IMVI	0.658	2.955	1.748	1.549	1.169	1.296	0.592	47	39	22	28	-10	< 1.00E-8	5.43E-5	> 1.00E-4	
M14	0.546	2.101	1.001	0.553	0.557	0.596	0.377	29	.	1	3	-31	< 1.00E-8	1.24E-5	> 1.00E-4	
MDA-MB-435	0.544	2.193	0.123	0.174	0.170	0.199	0.214	-77	-68	-69	-64	-61	< 1.00E-8	< 1.00E-8	< 1.00E-8	
SK-MEL-2	0.753	1.229	0.813	0.689	0.623	0.659	0.292	13	-9	-17	-13	-61	< 1.00E-8	3.92E-8	5.87E-5	
SK-MEL-28	0.592	1.616	1.114	1.096	1.009	0.906	0.409	51	49	41	31	-31	3.42E-8	3.14E-5	> 1.00E-4	
SK-MEL-5	0.929	3.036	1.179	1.059	0.603	0.469	0.112	12	6	-35	-50	-88	< 1.00E-8	1.41E-7	1.03E-5	
UACC-257	0.905	1.677	1.053	1.172	1.157	1.093	0.578	19	35	33	24	-36	< 1.00E-8	2.53E-5	> 1.00E-4	
UACC-62	0.902	2.733	1.638	1.667	1.504	1.282	0.422	40	42	33	21	-53	< 1.00E-8	1.91E-5	9.03E-5	
Ovarian Cancer																
IGROV1	0.486	1.619	0.900	0.698	0.645	0.452	0.200	37	19	14	-7	-59	< 1.00E-8	4.61E-6	6.75E-5	
OVCAR-3	0.705	2.008	0.689	0.519	0.469	0.450	0.341	-2	-26	-33	-36	-52	< 1.00E-8	< 1.00E-8	7.83E-5	
OVCAR-4	0.559	1.154	0.969	0.876	0.776	0.683	0.451	69	53	37	21	-19	1.58E-7	3.30E-5	> 1.00E-4	
OVCAR-5	0.593	1.523	1.173	0.947	0.923	0.754	0.690	62	38	35	17	10	3.24E-8	> 1.00E-4	> 1.00E-4	
OVCAR-8	0.588	2.091	1.119	0.711	0.653	0.609	0.396	35	8	4	1	-33	< 1.00E-8	1.10E-5	> 1.00E-4	
NCI/ADR-RES	0.543	2.041	0.746	0.552	0.527	0.479	0.453	14	1	-3	-12	-17	< 1.00E-8	1.48E-7	> 1.00E-4	
SK-OV-3	0.584	1.501	0.918	0.826	0.785	0.648	0.473	36	26	22	7	-19	< 1.00E-8	1.85E-5	> 1.00E-4	
Renal Cancer																
786-0	0.584	2.539	1.290	1.195	0.922	0.677	0.404	36	31	17	5	-31	< 1.00E-8	1.36E-5	> 1.00E-4	
A498	1.700	2.530	1.583	1.523	1.324	1.093	0.863	-7	-10	-22	-36	-49	< 1.00E-8	< 1.00E-8	> 1.00E-4	
ACHN	0.411	1.850	1.050	0.927	0.729	0.595	0.449	44	36	22	13	3	< 1.00E-8	> 1.00E-4	> 1.00E-4	
CAKI-1	0.648	2.636	1.075	1.331	1.098	0.912	0.518	21	34	23	13	-20	< 1.00E-8	2.50E-5	> 1.00E-4	
RXF 393	0.948	1.741	1.024	0.967	1.083	0.963	0.630	10	2	17	2	-34	< 1.00E-8	1.13E-5	> 1.00E-4	
SN12C	0.643	2.536	1.539	1.205	1.040	0.888	0.626	47	30	21	13	-3	< 1.00E-8	6.70E-5	> 1.00E-4	
UO-31	0.655	1.709	0.898	0.979	0.883	0.628	0.290	23	31	22	-4	-56	< 1.00E-8	6.92E-6	7.75E-5	
Prostate Cancer																
PC-3	0.698	2.242	1.142	1.072	0.940	0.969	0.572	29	24	16	18	-18	< 1.00E-8	3.11E-5	> 1.00E-4	
DU-145	0.460	1.687	0.706	0.468	0.317	0.352	0.296	20	1	-31	-24	-36	< 1.00E-8	1.05E-7	> 1.00E-4	
Breast Cancer																
MCF7	0.419	2.151	0.599	0.651	0.540	0.470	0.336	10	13	7	3	-20	< 1.00E-8	1.34E-5	> 1.00E-4	
MDA-MB-231/ATCC	0.681	1.506	1.285	0.797	0.596	0.650	0.593	73	14	-13	-5	-13	2.47E-8	3.37E-7	> 1.00E-4	
HS 578T	1.268	2.199	1.479	1.434	1.437	1.231	0.950	23	18	18	-3	-25	< 1.00E-8	7.24E-6	> 1.00E-4	
BT-549	1.240	2.397	1.903	1.545	1.385	1.226	0.815	57	26	12	-1	-34	1.72E-8	8.26E-6	> 1.00E-4	
MDA-MB-468	0.767	1.617	1.075	0.959	0.811	0.705	0.510	36	23	5	-8	-34	< 1.00E-8	2.44E-6	> 1.00E-4	

Mean Graphs

Report Date :December 09, 2013

Test Date :April 08, 2013

